PL421954A1 - Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications - Google Patents

Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications

Info

Publication number
PL421954A1
PL421954A1 PL421954A PL42195417A PL421954A1 PL 421954 A1 PL421954 A1 PL 421954A1 PL 421954 A PL421954 A PL 421954A PL 42195417 A PL42195417 A PL 42195417A PL 421954 A1 PL421954 A1 PL 421954A1
Authority
PL
Poland
Prior art keywords
prodh
expression
nucleic acid
pox
pox protein
Prior art date
Application number
PL421954A
Other languages
Polish (pl)
Other versions
PL239994B1 (en
Inventor
Jerzy PAŁKA
Ilona Zaręba
Nafis RAHMAN
Arkadiusz SURAŻYŃSKI
Wojciech Miltyk
Original Assignee
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Białymstoku filed Critical Uniwersytet Medyczny W Białymstoku
Priority to PL421954A priority Critical patent/PL239994B1/en
Priority to PCT/PL2018/000061 priority patent/WO2018236232A1/en
Publication of PL421954A1 publication Critical patent/PL421954A1/en
Publication of PL239994B1 publication Critical patent/PL239994B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem niniejszego zgłoszenia jest dwuniciowy kwas nukleinowy do wyciszania ekspresji genu kodującego białko PRODH/POX w komórce, wektor ekspresyjny do wyciszania ekspresji genu kodującego białko PRODH/POX zawierający taki dwuniciowy kwas nukleinowy, komórka gospodarza zawierająca taki dwuniciowy kwas nukleinowy lub wektor, klon komórkowy z wyciszoną ekspresją genu kodującego białko PRODH/POX zawierający taki dwuniciowy kwas nukleinowy lub wektor, kompozycja farmaceutyczna do wyciszania ekspresji genu kodującego PRODH/POX w organizmie zawierająca taki dwuniciowy kwas nukleinowy lub wektor oraz farmaceutycznie akceptowalny nośnik lub rozcieńczalnik. Zgłoszenie obejmuje ponadto sposób in vitro wyciszania ekspresji genu kodującego białko PRODH/POX w komórce, w którym wprowadza się taki dwuniciowy kwas lub wektor i utrzymuje się komórkę z tak wprowadzonym dwuniciowym kwasem nukleinowym lub wektorem w warunkach i przez czas wystarczający do osiągnięcia wyciszenia ekspresji genu kodującego białko PRODH/POX w komórce. Przedmiotem zgłoszenia jest także taki dwuniciowy kwas nukleinowy do zastosowania w terapii, w leczeniu i/lub profilaktyce zaburzenia lub choroby charakteryzującej się zaburzonym metabolizmem proliny, korzystnie choroby nowotworowej, zwłaszcza raka sutka, zespołu Marfana, zespołu Ehlersa-Danlosa i wrodzonej łamliwości kości, do hamowania wzrostu i/lub proliferacji komórki nowotworowej, do indukcji apoptozy i/lub autofagii, do zastosowania w diagnostyce, zwłaszcza w diagnostyce chorób charakteryzujących się zaburzonym metabolizmem proliny, korzystnie choroby nowotworowej, zwłaszcza raka sutka, zespołu Marfana, zespołu Ehlersa-Danlosa i wrodzonej łamliwości ości, do wytwarzania linii komórkowej wykazującej wyciszoną ekspresję genu kodującego PRODH/POX, do zastosowania do wytwarzania organizmu transgenicznego innego niż człowiek wykazującego wyciszoną ekspresję genu kodującego białko PRODH/POX, do zastosowania do wytwarzania klonu komórek wykazującego wyciszoną ekspresję genu kodującego białko PRODH/POX, korzystnie klonu komórek MCF-7 z wyciszoną ekspresją genu kodującego białko PRODH/POX. Przedmiotem zgłoszenia jest także jednoniciowy kwas nukleinowy do oznaczania ekspresji transkryptu genu kodującego białko PRODH/POX w komórce zawierający co najmniej jedną sekwencje o długości co najmniej 15 nukleotydów, która jest zasadniczo komplementarna na co najmniej części swojej długości do mRNA kodującego białko PRODH/POX. Przedmiotem niniejszego wynalazku jest również taki jednoniciowy kwas nukleinowy do zastosowania do wytwarzania mikromacierzy do identyfikacji ekspresji transkryptu genu kodującego białko PRODH/POX, do zastosowania do uzyskania sekwencji co najmniej części długości cDNA lub mRNA genu kodującego białko PRODH/POX w komórce.The subject of the present application is a double-stranded nucleic acid for silencing the expression of a gene encoding a PRODH / POX protein in a cell, an expression vector for silencing the expression of a gene encoding a PRODH / POX protein containing such a double-stranded nucleic acid, a host cell containing such a double-stranded nucleic acid or vector, a silenced cell clone expressing a gene encoding a PRODH / POX protein containing such a double-stranded nucleic acid or vector, a pharmaceutical composition for silencing the expression of a gene encoding PRODH / POX in an organism containing such a double-stranded nucleic acid or vector, and a pharmaceutically acceptable carrier or diluent. The application further includes an in vitro method of silencing the expression of a gene encoding PRODH / POX protein in a cell in which such a double-stranded acid or vector is introduced and the cell is maintained with the double-stranded nucleic acid or vector introduced in this way under conditions and for a time sufficient to achieve silencing expression of the coding gene PRODH / POX protein in the cell. The subject of the application is also such a double-stranded nucleic acid for use in therapy, in the treatment and / or prevention of a disorder or disease characterized by disturbed proline metabolism, preferably cancer, in particular breast cancer, Marfan syndrome, Ehlers-Danlos syndrome and congenital bone fragility, for inhibition tumor cell growth and / or proliferation, for induction of apoptosis and / or autophagy, for use in diagnostics, especially in the diagnosis of diseases characterized by disturbed proline metabolism, preferably cancer, in particular breast cancer, Marfan syndrome, Ehlers-Danlos syndrome and inborn bone fragility , for the production of a silenced expression of a PRODH / POX gene encoding gene, for use in the production of a non-human transgenic organism expressing a silenced expression of a PRODH / POX protein, for use in the production of a cell clone expressing silenced expression of the gene encoding PRODH / POX protein, preferably a MCF-7 cell clone silenced expression of the gene encoding PRODH / POX protein. The subject of the application is also a single-stranded nucleic acid for determining the expression of a transcript of a gene encoding the PRODH / POX protein in a cell comprising at least one sequence at least 15 nucleotides in length, which is substantially complementary at least part of its length to the PRODH / POX protein encoding mRNA. The present invention also relates to such a single-stranded nucleic acid for use in the production of microarrays for identifying expression of a transcript of a gene encoding a PRODH / POX protein, for use in obtaining a sequence of at least a portion of the length of the cDNA or mRNA of the gene encoding the PRODH / POX protein in a cell.

PL421954A 2017-06-20 2017-06-20 Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications PL239994B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL421954A PL239994B1 (en) 2017-06-20 2017-06-20 Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications
PCT/PL2018/000061 WO2018236232A1 (en) 2017-06-20 2018-06-19 Nucleic acids for silencing an expression of a gene encoding a prodh/pox protein and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL421954A PL239994B1 (en) 2017-06-20 2017-06-20 Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications

Publications (2)

Publication Number Publication Date
PL421954A1 true PL421954A1 (en) 2019-01-02
PL239994B1 PL239994B1 (en) 2022-02-07

Family

ID=63244932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL421954A PL239994B1 (en) 2017-06-20 2017-06-20 Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications

Country Status (2)

Country Link
PL (1) PL239994B1 (en)
WO (1) WO2018236232A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053323A2 (en) * 2000-01-24 2001-07-26 Ramot University Authority For Applied Research & Industrial Development Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053323A2 (en) * 2000-01-24 2001-07-26 Ramot University Authority For Applied Research & Industrial Development Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"shRNA konstrukty; sekwencje 1,3 zgłoszenia", GPP WEB PORTAL, 3 April 2017 (2017-04-03), Retrieved from the Internet <URL:https://portals.broadinstitute.org/gpp/public/gene/details?geneId=102724788> *
WEI LIU ET AL, MIRNA AND PROLINE METABOLISM IN CANCER, CHAPTER 15, 24 January 2013 (2013-01-24) *

Also Published As

Publication number Publication date
WO2018236232A1 (en) 2018-12-27
WO2018236232A4 (en) 2019-03-07
PL239994B1 (en) 2022-02-07

Similar Documents

Publication Publication Date Title
Wang et al. The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling
Chen et al. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5
Qu et al. MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene
Yang et al. mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells
Yamasaki et al. Angiogenic microRNA‐210 is present in cells surrounding osteonecrosis
Sun et al. MiR‐205 promotes endothelial progenitor cell angiogenesis and deep vein thrombosis recanalization and resolution by targeting PTEN to regulate Akt/autophagy pathway and MMP2 expression
Xu et al. Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B
Griner et al. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway
Yang et al. MORC4 is a novel breast cancer oncogene regulated by miR‐193b‐3p
BR112013001918A2 (en) vegfa-targeted sirna and in vivo treatment methods
Yang et al. mmu_circ_0000790 is involved in pulmonary vascular remodeling in mice with HPH via microRNA-374c-mediated FOXC1
Wu et al. MicroRNA-34a modulates the Notch signaling pathway in mice with congenital heart disease and its role in heart development
Chen et al. Effect of miR-29b on the proliferation and apoptosis of pulmonary artery smooth muscle cells by targeting Mcl-1 and CCND2
Yue et al. TAZ is highly expressed in gastric signet ring cell carcinoma
Makeyev et al. Molecular basis of Williams-Beuren syndrome: TFII-I regulated targets involved in craniofacial development
Cai et al. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance
Kagan et al. Lysyl oxidase and lysyl oxidase-like enzymes
Zhou et al. LncRNA GAS5 sponges miRNA-221 to promote neurons apoptosis by up-regulated PUMA under hypoxia condition
Xie et al. LOXL1-AS1/miR-515-5p/STAT3 positive feedback loop facilitates cell proliferation and migration in atherosclerosis
US20210123101A1 (en) Mirna marker and kit associated with postmenopausal osteoporosis
Lin et al. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases
Flórez et al. Analysis of vascular endothelial growth factor gene expression in the tissues of patients with chronic venous insufficiency
Jamal et al. BTYNB, an inhibitor of RNA binding protein IGF2BP1 reduces proliferation and induces differentiation of leukemic cancer cells
PL421954A1 (en) Bifilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications, expressive vector, host cell, cell clone, pharmaceutical composition, in vitro method for calming expression of PRODH/POX protein coding gene, monofilar nucleic acid for calming expression of PRODH/POX protein coding gene and its applications
CN110616265A (en) Molecular marker for preventing, diagnosing and treating tongue squamous carcinoma and application thereof